Vertex Ends Part of Telaprevir Study for Hepatitis C

Vertex Pharmaceuticals Inc. discontinued one part of a clinical study evaluating its hepatitis C treatments.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.